Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Opioid related disorder (ORD) is a chronic condition characterized by the compulsive use of opioids, leading to significant physical, psychological, and social impairments. According to Alexander M. Dydyk et al., opioid use disorder (OUD) affects over 16 million individuals globally. According to the opioid related disorder pipeline analysis by Expert Market Research, there is a growing focus on advanced therapies, including long-acting formulations, monoclonal antibodies, and biologics, aimed at reducing relapse and overdose risks. Key factors driving growth include increasing opioid misuse, rising overdose fatalities, and supportive government initiatives.
-
Major companies involved in the opioid related disorder pipeline analysis include Filament Health Corp., BioXcel Therapeutics Inc., and others.
-
Leading drugs currently in the pipeline include PEX010-Assisted Therapy, BXCL501, INDV-2000, and others.
-
The growth in the pipeline is driven by increasing investment in novel non-addictive therapies, expansion of combination treatments, and advancements in biologics and small molecules targeting withdrawal and relapse prevention.
Report Coverage
The Opioid Related Disorder Pipeline Analysis Report by Expert Market Research gives comprehensive insights into opioid related disorder therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for opioid related disorder. The opioid related disorder report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The opioid related disorder pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with opioid related disorder treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to opioid related disorder.
Read more about this report - Request a Free Sample
Opioid Related Disorder Pipeline Outlook
Opioid related disorder (ORD) is a chronic condition marked by compulsive opioid use, causing significant physical, psychological, and social impairment. It arises from prolonged exposure to prescription opioids, heroin, or synthetic opioids, leading to dependence, tolerance, and withdrawal symptoms. Genetic, environmental, and behavioral factors further increase susceptibility.
Opioid related disorder treatments involve medication for opioid use disorder (MOUD), such as buprenorphine, methadone, and extended-release naltrexone, alongside counseling and behavioral therapy to reduce relapse and enhance patient outcomes. In the ORD drug pipeline, innovative long-acting formulations of buprenorphine and methadone are being developed to improve adherence, minimize misuse risk, and expand treatment access, reflecting notable progress in the market.
Opioid Related Disorder Epidemiology
According to Alexander M. Dydyk et al., opioid use disorder (OUD) affects approximately 16 million people globally, including 2.1 million in the United States. According to the same source, OUD contributes to over 120,000 deaths worldwide and 47,000 deaths in the United States annually. Men are more prone to opioid dependence and overdoses, while women receive opioids for analgesia more frequently. Opioid-related mortality peaks between ages 40–50, whereas heroin overdoses are most common among individuals aged 20–30 years.
Opioid Related Disorder – Pipeline Therapeutic Assessment
This section of the report covers the analysis of opioid related disorder drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The opioid related disorder pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Natural Metabolites
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
- Oral
- Parenteral
- Others
Opioid Related Disorder Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, accounting for 40%, covers a major share of the total opioid related disorder clinical trials, reflecting strong clinical activity and potential breakthroughs. Phase I contributes 18%, phase III 16%, and phase IV 16%. This robust distribution across phases indicates a growth outlook, fostering innovation and expanding treatment options in the market.
Opioid Related Disorder Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the opioid related disorder pipeline analysis include small. The opioid related disorder report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for opioid related disorder. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are emerging as potential treatments for opioid-related disorder. For example, semaglutide and liraglutide are under clinical investigation for their ability to modulate the brain’s reward system and reduce opioid cravings. These drugs act on the mesolimbic pathway, helping prevent relapse without the risk of addiction associated with traditional opioid-based therapies.
Opioid Related Disorder Clinical Trials – Key Players
The EMR report for the opioid related disorder pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed opioid related disorder therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in opioid related disorder clinical trials:
- Filament Health Corp.
- BioXcel Therapeutics Inc.
- Indivior Inc.
- Boehringer Ingelheim
- Jazz Pharmaceuticals
- SafeMedWaste, Inc.
- Friends Research Institute, Inc.
- Go Medical Industries Pty Ltd.
- Clinilabs, Inc.
- Altasciences Company Inc.
Opioid Related Disorder – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for opioid related disorder. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of opioid related disorder drug candidates.
Drug: PEX010-Assisted Therapy
PEX010 is a psychedelic-assisted therapy drug being developed by Filament Health Corp. for treating opioid use disorder (OUD). This Phase 2 study is assessing the feasibility, safety, and participant retention while administering PEX010 in combination with psychotherapy. Standardized to contain 25mg or 35mg psilocybin, the drug is being given in two sessions alongside cognitive behavioral therapy. The study is examining neurocognitive, behavioral, and clinical outcomes to evaluate its potential as a novel OUD treatment.
Drug: BXCL501
Sublingual Dexmedetomidine (BXCL501) is being developed by the New York State Psychiatric Institute to treat opioid withdrawal in individuals with opioid use disorder. This Phase 1B study is examining the safety and efficacy of BXCL501 compared to lofexidine and placebo during a 7-day inpatient methadone taper. BXCL501 is a sublingual, orally dissolving film formulation of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist, designed to reduce withdrawal symptoms such as anxiety, muscle pain, and insomnia, while minimizing cardiovascular side effects. The study is enrolling 160 participants across three sites.
Drug: INDV-2000
INDV-2000, a potent and highly selective oral Orexin-1 Receptor (OX1R) antagonist, is being evaluated by Indivior Inc. in a Phase II proof-of-concept and dose-ranging study for individuals with moderate to severe opioid use disorder (OUD). This study is examining the safety, efficacy, and dose-response relationship of INDV-2000 in participants transitioning from short-term buprenorphine treatment to a non-opioid therapy. The drug is showing promise in reducing opioid intake and craving in preclinical models and is actively contributing to the development of non-opioid treatment options.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Opioid Related Disorder Pipeline Insight Report
- Which companies/institutions are leading the opioid related disorder drug development?
- Which company is leading the opioid related disorder pipeline development activities?
- What is the current opioid related disorder commercial assessment?
- What are the opportunities and challenges present in the opioid related disorder pipeline landscape?
- What is the efficacy and safety profile of opioid related disorder pipeline drugs?
- Which company is conducting major trials for opioid related disorder drugs?
- Which companies/institutions are involved in opioid related disorder collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in opioid related disorders?
Reasons To Buy This Report
The Opioid Related Disorder Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for opioid related disorder. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into opioid related disorder collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Opioid Use Disorder Market Report
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share